Introduction
Tissue homoeostasis is essential for the maintenance of multicellular organisms and requires a fine tuned balance between cell proliferation and death. Elucidation of the molecular mechanisms involved in the latter process progressed exponentially over the last two decades and provided significant insights into the comprehension of pathogenesis of human diseases. Amongst the cell death mechanism characterized in mammals, namely apoptosis, necrosis and autophagy, programmed cell death or apoptosis is currently the best characterized. This a discrete and active process that was originally identified on morphological characteristics, including cell shrinkage, membrane blebbing, chromatine condensation and nuclear fragmentation . Apoptosis has been involved in embryonic development, [1 ] adult tissue homeostasis and cell response to noxious stimuli. Its triggering can proceed through an extrinsic or intrinsic pathway .
[2 ]
The intrinsic pathway can be initiated by the release of proapototic molecules such as cytochrome c, from damaged mitochondria, which activate the intracellular receptor Apaf-1 (Apoptotic Protease-Activating Factor 1) forming with caspase-9 a proteotically active structure called the apoptosome . Extrinsic activation of apoptosis, on the other hand, can occur upon stimulation of a cell membrane [3 ] associated death receptor (DR). To date eight DRs have been described: TNF-R1 (CD120a) , , Fas (APO-1 or CD95) , , TRAMP EDA-R (ectodermal dysplasia receptor) . The best characterized are TRAIL-R1/R2 and Fas, which have been shown to play a crucial [19 ] role in the immune system, in both immune-cell mediated cytotoxicity and downregulation of immune responses. Upon binding with their cognate ligands, these receptors form aggregates that enable the recruitment of the adapter molecule FADD (MORT1) and the [20 ] initiator protease caspase-8 (FLICE, MACH, MCH5) , hence forming the so-called Death-Inducing Signalling Complex (DISC) in [21 -23 ] which caspase-8 is processed and activated . Both intrinsic and extrinsic systems transmit signals through protein protein interactions [24 ] that are mediated by homologous and evolutionarily related protein-interaction motifs, including the death domain (DD), the death effector domain (DED) or the caspase-recruitment domain (CARD). Execution of the apoptotic process in all instances is dependent on a family of intracellular cysteine proteases, called caspases , . These interactions induce caspase activation by cleavage in a close proximity [7 25 -27 ] that enables the activation of the caspase cascade culminating in the cleavage of various substrates, such as lamins, fodrin, gelsolin, [28 ] actin or the Inhibitor of Caspase-Activated DNase (ICAD), leading to cell dismantle ( ). Figure 1 Dysregulation of apoptosis, however, can lead to various pathologies. Defective apoptosis generates cell accumulation that characterizes autoimmune disease and cancer, whereas excessive apoptosis plays a role in neurodegenerative diseases, heart failure and
AIDS
. It appears thus essential to understand more thoroughly how this process is regulated at the cellular level, but also with respect [29 ] to human diseases, in order to design new therapeutic strategies that would circumvent apoptotic dysregulation and prove beneficial for human health. To avoid uncontrolled cell or tissue damage, apoptosis is tightly controlled by a collection of cellular inhibitors, such as the Proteins of the Inhibitor of Apoptosis (IAP) family which regulate apoptosis at the post-mitochondrial level by binding to and inhibiting caspase-3, -6, -7 and -9, the Bcl-2 family members which regulate apoptosis at the mitochondrial level , and c-FLIP, that negatively
interferes with DR-induced cell death, upstream of the mitochondrial events . This review focuses on c-FLIP whose dysregulation has [25 ] been identified in various diseases including multiple sclerosis, Alzheimer s disease, diabetes mellitus, rheumatoid arthritis, cardiovascular ' disorder and various cancers.
FLICE-Inhibitory Protein or c-FLIP
Viral FLICE-inhibitory proteins (v-FLIPs), were initially discovered by bioinformatic search for novel virus-encoded apoptosis-regulatory molecules containing a DED. Mammalian homologues of v-FLIPs, also designed c-FLIP, CASH, Casper, CLARP, FLAME, I-FLICE, MRIT and usurpin , share structural and sequence homologies with caspase-8 and -10, upstream caspases [30 -37 ] involved in the initiation of DR-induced apoptosis, such as Fas/Apo1, TRAIL or TNFR-1. c-FLIP contains two serial amino-terminal DEDs followed by a carboxy-terminal extension comprising a caspase-homologous domain similar to caspase-8 and caspase-10. However, owing to the substitution of several amino acids conserved in caspases, such as the cysteine residue within the QACXG-motif and the histidine residue within the HG-motif, c-FLIP is devoid of proteolytic activity , . Consistently, a protective role for c-FLIP in [25 38 ] DR-induced apoptosis was found in fibroblast cell lines derived from c-FLIP-knockout mice . The DEDs of c-FLIP bind to the DED [39 ] of the adaptor protein FADD, acting as dominant-negative inhibitors of the processing and release of active caspase-8 or 10 to the -cytosol.
Although cellular FLIPs exists as multiple splice variants at the mRNA level, it appears that only two variants are expressed as Fas, TRAIL-R1, TRAIL-R2, TRAMP and TNF-R1  ,  ,  , . At comparable expression levels, [32 -34 36 41 42 ] however, c-FLIP (L) is a more potent inhibitor than c-FLIP (S) . In the canonical Fas and TRAIL-induced caspase activation pathway, [36 ] both caspase-8 and c-FLIP (L) are partially processed at the DISC level , . c-FLIP (L) contains a conserved aspartic-acid cleavage [43 44 ] site (Asp-341) between the p20-and p10-like domains , which can be cleaved . In c-FLIP (L) overexpressing cells, [32 ] in vitro procaspase-8 is found in the DISC partially processed as a p44/41 fragment , , corresponding to the first cleavage of procaspase-8 [43 45 ] generally observed upon Fas or TRAIL stimulations. In contrast, c-FLIP (S) forms a caspase-8/c-FLIP (S) heterocomplex, in which no processing of caspase-8 occurs , . Thus, although able to inhibit DR-induced cell death, both isoforms proceed differently, [43 45 ] suggesting that a) these isoforms are not redundant and b) their non apoptosis-inhibitory functions, yet to be determined, could differ importantly.
When overexpressed, c-FLIP (L), but not c-FLIP (S), has been reported to be pro-apoptotic . This cytocidal effect was suggested [33 ] to result from the non-physiological aggregation of its pro-apoptotic interaction partners FADD and caspase-8 under conditions of overexpression. We have recently provided molecular evidences that the heterocomplex c-FLIP (L)/caspase-8, contrarily to c-FLIP (S)/caspase-8, could exhibit a proteolytic activity, at the DISC level . While physiologically restricted to the plasma membrane, this [45 ] proteolytic activity could account for the pro-apoptotic activity of c-FLIP (L) under non-physiological conditions.
In Fas-stimulated cells, c-FLIP (L) was suggested to be involved in the regulation of gene expression by the extracellular [49 -51 ] mutant of FADD lacking the caspase-dimerizing death effector domain, and those from mice overexpressing the poxvirus serpin, CrmA, an inhibitor of caspases downstream of FADD, are completely protected from Fas-dependent cytotoxicity. Neither transgene afforded protection from apoptosis induced during thymocyte selection and neither led to the lymphoproliferative disorders associated with deficiencies in Fas. Nevertheless, in FADD dominant negative mice, early thymocyte development was retarded and peripheral lymphocyte pools were devoid of normal populations of T cells, suggesting that FADD is probably involved in T cell development and activation . This is concordant with earlier observations indicating that Fas-engagement could induce co-stimulation of [49 -51 ] TCR-induced lymphocyte proliferation in resting human and murine memory T cells . Accordingly, Fas engagement was shown [52 -54 ] to induce neurite growth through ERK , and c-FLIP (L) was recently shown to enhance TCR-triggered proliferation in transgenic mice [55 ] . [47 ] Gene-targeted inactivation of either FADD , caspase-8 or c-FLIP , in mice, provided important information on the [49 ] [56 ] [39 ] contribution of DRs in human embryonic development and human diseases. Although carrying opposite regulatory functions, caspase-8 and c-FLIP deficient mice, exhibit a similar embryonic phenotype as FADD / mice. These mice die from day 10.5 to 12.5 of − − embryogenesis, with apparent heart defects. However, neither FADD-deficient nor c-FLIP-deficient embryos demonstrate changes in cell 3 13 death rate, suggesting that the developmental defects in these mutant mice may be independent of apoptosis. However, unlike FADD / − − and caspase-8 / cells, FLIP / embryonic fibroblasts are highly sensitive to apoptotic stimuli that involve death receptors. This result is
consistent with the predicted role of c-FLIP to counteract FADD and caspase-8 in the regulation of DR-induced apoptosis.
c-FLIP (L) is expressed in many tissues, but most abundantly in the heart, skeletal muscle, lymphoid tissues and kidney. In lymphatic tissues, an additional 25 kDa c-FLIP species is detectable, which corresponds to the predicted size of c-FLIP (S) . Although expressed [35 ] constitutively in many cell types, c-FLIP is a very short-lived protein , , , whose expression can be regulated by a variety of [ synthetic PPAR ligands , sodium butyrate , interferon and E1A were shown to downregulate c-FLIP expression, [64 ] [65 ] β [66 ] [ 67 ] through mechanisms that could involve the ubiquitin-proteasome pathway. Degradation of c-FLIP is dramatically elevated in TRAF2-deficient mice embryonic fibroblasts . More recently, hemin-mediated erythroid differenciation was shown to downregulate [68 ] both splicing variants of c-FLIP in K562 cells . [69 ] In contrast, the PI3K/Akt , and MAPK (Mitogen-Activated Protein Kinase) , pathways, stem cell factor and the [70 -72 ] [ 73 74 ]
Calcium/Calmodulin-dependent protein kinase II , increased c-FLIP expression at the transcriptional level. Amongst the stimuli [76 ] implicated so far in the regulation of c-FLIP expression, the discovery that c-FLIP expression was up-regulated by NF-kB signals, provided for the first time a molecular explanation of the well-known TNF-induced NF-kB-dependent survival pathway , , . [79 ]
FLIP and human diseases Lymphoproliferative syndrome with autoimmunity
Autoimmune lymphoproliferative or Canale and Smith syndrome (ALPS) is a human disorder that is characterized by defective lymphocyte apoptosis, lymphadenopathy, splenomegaly and autoimmunity . Its pathogenesis has been attributed to dysregulated [80 ] lymphocyte homeostasis, a process involving negative selection and activation-induced cell death (AICD) . Genetically, ALPS was [80 ] first described in MRL and in MRL mice, two animal models of human lupus, which exhibit mutations in Fas receptor and Fas lpr gld ligand respectively . In humans, ALPS is defined by functional analysis of lymphocyte sensitivity to Fas-induced apoptosis in [81 ] in vitro 3 categories ranging from a complete (APLS 0) or partial Fas deficiency (ALPS Ia and II) to an absence of defect in the Fas pathway (ALPS Ib and III) . So far, heterozygous mutations in Fas, Fas ligand or caspase-10 underlie most cases of human inherited genetic [81 ] deficiency with deregulated lymphocyte proliferation. Recently, inherited caspase-8 deficiency has been described in human patients . [82 ] Individuals with homologous mutations in caspase-8 manifest defective lymphocyte apoptosis and homeostasis but, unlike individuals affected with ALPS, also have defects in T lymphocytes, B lymphocytes and natural killer cells activation, which leads to immunodeficiency. Surprisingly, caspase-8 deficiency in humans is compatible with normal development, in contrast to mice for which caspase-8 gene inactivation is lethal , . The observation that c-FLIP (L) expression is modulated in activated T cells in an [56 82 ] IL-2-dependent manner suggests that c-FLIP (L) could play a role in the control of T-cell activation , . This idea is consistent [36 83 -85 ] with a recent report providing evidence that c-FLIP (L), rather than preventing AICD, could enhance TCR-triggered proliferation . [47 ] Since c-FLIP can in the one hand inhibit cell death and in the other hand contribute to TCR-triggered lymphocyte proliferation, further experiments will be required before considering its therapeutic modulation in the context of lymphoproliferative diseases.
Alzheimer s Disease

'
Alzheimer s disease (AD) is a neurodegenerative disease characterized by elevated levels of -Amyloid (A ) in the brains . Senile ' β β [86 ] plaques deposition of A and dysregulated apoptosis are though to be involved in the pathogenesis of Alzheimer s disease , . A β '
[29 87 ] β -induced neuronal death has been attributed to be triggered by two members of the TNF superfamily, namely p75(NGFR) nerve growth factor receptor and Fas through an indirect mechanism. It has been shown that A binds to p75(NGFR) and activates neuronal cell death shown to play a substantial role in this process , suggesting a critical role for the JNK pathway in the regulation of A -induced [90 ] β apoptosis in AD patients and the potential involvement of inhibitory molecules located downstream of the Fas signalling pathway, such as c-FLIP. The JNK-Fas ligand pathway can also be triggered by survival factor withdrawal in neurons , or by stress stimuli as UV-lights [92 ] or gamma irradiation , . Interestingly, a recent report suggested that a viral homologue of c-FLIP, the HHV8-v-FLIP could rescue [93 94 ] growth factor withdrawal-induced apoptosis in the TF-1 human myeloid leukemia cell line . In addition, studies evaluating the [95 ] expression levels of caspases or apoptosis-related proteins, in human postmortem brain cerebellum or frontal cortex tissues of patients with 4 13 AD
Multiple sclerosis
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS) that is characterized pathologically by perivascular mononuclear cell infiltrates and myelin damage . Experimental autoimmune encephalomyelitis (EAE) is an animal model [98 ] of this disease that is characterized by increased permeability of the blood-brain barrier, perivascular inflammatory infiltrates comprised of T cells, B cells, macrophages, and granulocytes, and demyelination leading to an ascending paralysis of the extremities. In this model, the principal targets of the autoimmune attack are oligodendrocytes and myelin.
Although the mechanisms causing myelin disruption and damage to axons in the CNS are still unclear, this autoreactive immune-mediated disorder is thought to be initiated by activated T lymphocytes recognizing myelin components of the CNS , and [99 ] autoreactive B lymphocytes directed against oligodendroglial and myelin antigens , . In animal EAE models, Fas-mediated [100 101 ] apoptosis of activated T cells and other inflammatory cells in the CNS modulates the inflammatory response . In the early phases of [102 ] the disease however the Fas pathway may be responsible for myelin destruction since administration of neutralizing antibody against Fas ligand was shown to suppress the acute progression phase of EAE . In patients with MS, the Fas pathway has also been suggested to [103 ] be involved . Nevertheless, as several DR-induced apoptotic signals are regulated by c-FLIPs, these findings demonstrate that effective apoptotic elimination of inflammatory cells to achieve disease remission may be crucial. Therefore, downregulation of c-FLIPs could prove beneficial for the prevention of MS pathogenesis.
Rheumatoid Arthritis (RA)
Rheumatoid arthritis (RA) is a chronic inflammation of the synovial joints characterized by infiltration of activated T cells, macrophages and plasma cells , . Its etiology although poorly understood, is thought to involve both impaired clearance of [117 118 ] activated infiltrating cells (T cells, macrophages) and increased cartilage and bone sensitivity to cell death. Human chondrocytes and [119 ] osteoblasts have been shown to express functionnal Fas receptor, and as T cells infiltrating the RA-affected joints express FasL [120 ] [121 , , it is thougth that the Fas pathway plays an important role in cartilage and bone destruction. Indeed, it has recently been shown that 122 ] arthritic lesions could be induced, , by persistent engrafted syngeneic lymphocytes overexpressing FasL . In contrast to Fas, in vitro [123 ] TRAIL was suggested to be a potent inhibitor of autoimmune arthritis and blocking endogenous TRAIL with soluble TRAIL-R1 impaired this inhibition and enhanced proliferation of autoreactive lymphocytes and synovial cells. Furthermore, by use of deficient mice, TRAIL has recently been shown to play an important role in autoimmune diseases and in particular in the clearance of autoreactive synovium-infiltrating cells in RA . The inhibitory effect of TRAIL on arthritis proceeds through inhibition of cell cycle progression [124 ] and/or cytokine production inhibition , . Interestingly, synoviocytes and particularly synovial macrophages which are thought to [116 125 ] be the main trigger of the inflammatory response in RA, via the production of TNF and IL-1 , are naturally sensitive to anti-Fas [126 ] monoclonal antibody-induced apoptosis , but particularly resistant to this process when isolated from arthritic mice and RA in vitro [127 ] patients , . Furthermore, RA synovial macrophages express high levels of c-FLIP , and c-FLIP expression was shown to be [128 129 ] [ 130 ] increased in synovial biopsy specimens from patients with early RA, especially in RA synovial macrophages which express high levels of c-FLIP.
Altogether, these data point to c-FLIP as an interesting therapeutic target for the treatment of rheumatoid arthritis for several reasons.
1) c-FLIP is involved in both Fas and TRAIL-induced apoptosis inhibition. 2) c-FLIP is highly expressed in RA macrophages which account for the sustained joint inflammation through TNF and IL-1. 3) Inhibiting TNF and IL-1 macrophage production, ameliorates RA symptoms and joint destruction . 4) c-FLIP expression is increased by TNF via NF-kB . Therefore, downregulating c-FLIP [126 ] [ 42 ] locally in activated infiltrating synovial T cells and macrophages could sensitize these cells to Fas-or TRAIL-induced clearance and prove useful for the treatment of RA. 5 13 Diabetes mellitus is the most common metabolic disease worldwide. Type 1 diabetes results from autoimmune destruction of Langerhans islets pancreatic cells causing insulin deficiency. Type 2 or noninsulin-dependent diabetes mellitus (NIDDM) is a polygenic β disease that accounts for more than 90 of cases of diabetes, in which long-term adaptation of pancreatic islets cells mass expansion in [131 ] to be involved in the destruction of insulin-producing cells and the development of diabetes, in a T-cell-dependent or -independent [132 ] manner . Overexpressing c-FLIP (L) in cells prevents from TNF-induced apoptosis , and predisposition of NOD mice to [133 ] β [134 ] develop autoimmune disease is usually attributed to defects in peripheral tolerance mechanisms, which has recently been attributed to the up-regulation of c-FLIP (L) in activated T cells . This suggests that the Fas pathway or death receptors of this family could also [135 ] contribute to the progression of the disease or associated side effects . Diabetic macular edema is the most prevalent cause of vision [124 ] loss in diabetes, was recently shown to result from leukocyte-mediated Fas-FasL-dependent retinal endothelial cell apoptosis . Taken [136 ] together, these data indicate that increasing c-FLIP expression in specific cells by therapeutic targeting may prove beneficial for the treatment of diabetes, or associated retinopathy.
Diabetes mellitus
Cardiovascular diseases
The cardiovascular system is continuously subjected to stressfull haemodynamic forces due to blood pressure and flow. Although essential for the maintenance of organic structure and function, this mechanical stress can eventually induce apoptosis and lead to cardiovascular disorders such as heart failure, hypertension or atherosclerosis . Some members of the TNF family could be involved [137 ] in these diseases.
TNF was shown to be elevated in the cardiomyocytes and in the circulation of heart failure patients , , and chronic [138 139 ] overexpression of TNF results in the development of a dilated cardiomyopathy also leading to heart failure . DNA microarray [140 ] analysis of a collection of human left ventricular myocardium samples obtained from explanted cardiomyopathic hearts from patients with end-stage heart failure undergoing heart transplantation, showed a clear reduction in expression of anti-apoptotic genes such as TNFR-1,c-FLIP and A20, together with an increase in expression of TRAIL .c-FLIP is highly expressed in the adult human and [141 ] murine healthy heart, but its expression is severely reduced in cardiomyocytes originating from cardiomyopathic hearts that have undergone apoptosis , . [35 142 ] Normal vascular endothelial cells express both Fas and FasL but are resistant to Fas-mediated apoptosis, however overexpression of FasL was shown to promotes atherosclerosis in a rabbit experimental model . Interestignly, vascular endothelial cells express c-FLIP [143 ] , but downregulation of its expression by oxidized lipids sensitize endothelial cells to DR-induced apoptosis, suggesting that c-FLIP [59 ] could play an important role in controlling vascular tissue destruction , and that dysregulated expression of c-FLIP could be [59 144 ] involved in the etiology and pathogenesis of atherosclerosis . [39 ] Although different, the pathological mechanisms underlying heart failure, hypertension or atherosclerosis are believed to be related to sustained mechanical overload or stress, leading to proliferation, differentiation or to cell death . With respect to apoptosis, c-FLIP [137 ] has been suggested to could play a major role in heart development as well as in pathogenesis of heart failure and atherosclerosis . [39 ] Interestingly, FADD-, caspase-8-or FLIP-, but not Fas-nor tumor-necrosis-factor receptor-1 (TNFR-1)-deficient mice, show symptoms of impaired heart development , , , , . Furthermore, the observation that the Fas-deficient mice phenotype differ from that [39 49 56 145 146 ] of FLIP-deficient mice, suggests that other receptors of the TNF superfamily, as TRAIL receptors, may play a major role in cardiovascular diseases. Therefore, therapeutic up-regulation of c-FLIP-expression levels might turn out to be useful for the treatment of cardiovascular diseases such as heart failure or atherosclerosis.
Cancer
Cancer is a malignant disease generally arising from impaired cellular homeostasis and resulting in the excessive accumulation of unwanted cells in the body, which eventually lead to a loss of organic function and death. Dysregulation of cellular homeostasis can be inherited or acquired. For example, neuroblastoma tumour cells show complex combinations of acquired genetic aberrations while [147 ] colon carcinomas result from multiple genetic alterations, some of which may be inherited, while others reflect somatic mutations. The latter may themselves be the indirect result of environmental factors such as diet , . The etiology and the progression of cancers [148 149 ] is the addition of cumulative genetic changes, combining both the activation of oncogenes with the inactivation of tumour suppressor genes.
In recent years it became evident that TRAIL receptors are key regulators of immune surveillance against tumours . Trail [150 -154 ] appears to be the most promising new anti-tumour therapeutic tool since this cytokine is capable of inducing apoptosis in tumour cells, but is devoid of severe toxicity towards normal cells, both and . However, not all tumour cells are sensitive to TRAIL, in vitro in vivo [155 ] and c-FLIP, which inhibits TRAIL-induced cell death, is often over-expressed in tumours and was suggested to be a tumour-progression 6 13 factor . Accordingly, expression of c-FLIP has been shown to correlate with resistance to Fas-induced apoptosis in [156 -158 ] in vitro certain tumour cell lines derived from B-cell lymphomas , and with tumour escape from T-cell immunity and enhanced tumour [159 -161 ] progression , . Moreover, abnormal overexpression of c-FLIP (L) is a frequent event in colon adenocarcinomas . In in vivo [157 173 176 -189 ] in vivo [183 190 191 ] can be achieved by a variety of stimuli inducing the downregulation of c-FLIP, such as antisense cDNA constructs , , short [192 193 ] In addition, overexpression of viral analogues of c-FLIP or c-FLIP (L) itself was shown to impair chemotherapy-induced 62 195 196 ] apoptosis , . Likewise, resistance to DR-or anti-tumour drug-induced apoptosis is often associated with a loss of function of [197 198 ] caspase-8, the major target of c-FLIPs
. Loss of caspase-8 expression has been shown to occur in a variety of tumour cells [199 -202 ] including the common childhood primitive neuroectodermal brain tumours/medulloblastomas, highly malignant human neuroblastomas,
Ewing tumours, and melanomas , . Reexpression of caspase-8 through promoter demethylation or gene transfer restored [173 202 -205 ] tumour cell sensitivity to DR-or chemotherapeutic drug-induced cell death , . [173 202 ] Taken together, since c-FLIP expression can be regulated by certain anti-tumour agents, monitoring c-FLIP-expression levels, might therefore, turn out to be of diagnostic value for certain tumours, and could improve cancer therapy at the clinical level.
Conclusions
The understanding of the molecular basis of apoptosis has dramatically progressed in the last decade and has led to the identification of many target genes whose dysregulated expression contributes substantially to human diseases. Amongst these target genes, c-FLIP, which plays a central role in the inhibition of death receptors of the TNF superfamilly, has been shown to be dysregulated in multiple sclerosis, Alzheimer s disease, diabetes mellitus, rheumatoid arthritis and cancer, as documented in this review. Therefore, developing ' analytical tools to evaluate c-FLIP expression in biological samples originating from these diseases would likely be beneficial to therapeutic strategies targeting immunologic or neurologic disorders associated with c-FLIP dysregulation.
Targeting c-FLIP may notably have beneficial impact in oncology. For the past decades, anti-tumour drug design strategies have mainly focused on inhibiting cellular proliferation. However, it is becoming increasingly clear that cell death dysregulation can also lead to neoplastic transformation and development. Therefore, strategies aiming at the restoration of the apoptotic machinery in tumour cells, may prove to be useful for the treatment of cancer patients in the future.
The growing number of c-FLIP expression regulators ( ) extends considerably the possibilities of developing novel therapeutic Table 1 protocols, which may prove useful in improving patient s care. Yet the molecular mechanisms of c-FLIP regulation still remains poorly ' understood and further studies are required, especially for the understanding of c-FLIP isoforms. Since c-FLIP is a major regulator of DR-induced apoptosis, and since dysregulated c-FLIP expression is associated with a growing number of pathologies, monitoring c-FLIP levels might be of diagnostic value, and drugs that specifically alter c-FLIP-expression levels will certainly turn out to be of therapeutic benefit.
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